2. Search Result
Search Result
Results for "

α-amylase activity

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

12

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N10413
    Diphlorethohydroxycarmalol

    		Glycosidase Metabolic Disease
    Diphlorethohydroxycarmalol, a kind of phlorotannin, is an orally active α-glucosidase and α-amylase inhibitor with IC50s of 0.16 mM and 0.53 mM, respectively. Diphlorethohydroxycarmalol has anti-diabetic activities .
    Diphlorethohydroxycarmalol
  • HY-149008
    α-Amylase-IN-3

    		Amylases Cholinesterase (ChE) Inflammation/Immunology
    α-Amylase-IN-3 (Compound 4) is the inhibitor for α-Amylase, AChE and AChE with IC50s of 18.04 μM, 21.04 μM and 22.2 μM, respectively. α-Amylase-IN-3 exhibits antioxidant activity. α-Amylase-IN-3 can be used in research of diabetes and oxidative stress associated disease .
    α-Amylase-IN-3
  • HY-132179
    Fucoidan
    2 Publications Verification

    		 Glycosidase Cardiovascular Disease Metabolic Disease Cancer
    Fucoidan, a biologically active polysaccharide, is an efficient inhibitor of α-amylase and α-glucosidase. Anticoagulant, antitumor, antioxidant and antisteatotic activities .
    Fucoidan
  • HY-155241
    α-Amylase/α-Glucosidase-IN-4

    		Glycosidase Amylases Metabolic Disease
    α-Amylase/α-Glucosidase-IN-4 (compound 5) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 0.15 μM and 1.10 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
    α-Amylase/α-Glucosidase-IN-4
  • HY-174319
    α-Amylase/α-Glucosidase-IN-20

    		Amylases Glycosidase Metabolic Disease
    α-Amylase/α-Glucosidase-IN-20 (Compound 6b) is a dual inhibitor of α-Amylase and α-Glucosidase with IC50s of 414.57 and 924.15 μM for α-Amylase and α-Glucosidase, respectively. α-Amylase/α-Glucosidase-IN-20 shows a potent anti-diabetic activity, promising for diabetes research .
    α-Amylase/α-Glucosidase-IN-20
  • HY-149557
    α-Amylase/α-Glucosidase-IN-5

    		Glycosidase Amylases Metabolic Disease
    α-Amylase/α-Glucosidase-IN-5 (compound 4l) is a dual inhibitor of α-glucosidase (Glucosidase) and α-amylase (Amylases) with IC50s of 5.96 μM and 1.62 μM, respectively. α-Amylase/α-Glucosidase-IN-4 has potential antidiabetic activity .
    α-Amylase/α-Glucosidase-IN-5
  • HY-156380
    α-Amylase/α-Glucosidase-IN-6

    		Amylases Glycosidase Metabolic Disease
    α-Amylase/α-Glucosidase-IN-6 (compound 5j) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 17.0 and 40.1 µM, respectively. α-Amylase/α-Glucosidase-IN-6 exhibits anti-hyperglycemic activities .
    α-Amylase/α-Glucosidase-IN-6
  • HY-168495
    α-Amylase-IN-12

    		Amylases Glycosidase Metabolic Disease
    α-Amylase-IN-12 (Compound 5e) is an α-amylase inhibitor (IC50: 0.15 mM) with a mixed inhibition. α-Amylase-IN-12 has an IC50 of 9.40 mM against α-glucosidase. α-Amylase-IN-12 promotes glucose uptake in yeast cells and exhibits significant antiglycation activity at high concentrations. α-Amylase-IN-12 can be used for the research of diabetes .
    α-Amylase-IN-12
  • HY-162169
    α-Amylase/α-Glucosidase-IN-8

    		Amylases Glycosidase Metabolic Disease
    α-Amylase/α-Glucosidase-IN-8 (Compound 7p) is a potent dual inhibitor of α-amylase and α-glucosidase, with IC50s of 10.19 and 10.33 μM, respectively. α-Amylase/α-Glucosidase-IN-8 has good anti-oxidant activity(IC50 = 14.93 μM). α-Amylase/α-Glucosidase-IN-8 can be used for the research of diabetes .
    α-Amylase/α-Glucosidase-IN-8
  • HY-N12263
    3,5,6,7,8,4'-Hexamethoxyflavone

    		Amylases Metabolic Disease
    3,5,6,7,8,4'-Hexamethoxyflavone is a inhibitor of α-Amylase with the inhibitory activity of 28.3% at 500 μM .
    3,5,6,7,8,4'-Hexamethoxyflavone
  • HY-172211
    α-Amylase/α-Glucosidase-IN-17

    		Amylases Glycosidase Metabolic Disease Cancer
    α-Amylase/α-Glucosidase-IN-17 (Compound 3) is an inhibitor of α-amylase and α-glucosidase, with IC50 values of 14.61 μM and 25.38 μM, respectively. α-Amylase/α-Glucosidase-IN-17 has certain inhibitory activity against A549 cancer cells. α-Amylase/α-Glucosidase-IN-17 has anti-tumor and anti-diabetic effects .
    α-Amylase/α-Glucosidase-IN-17
  • HY-162390
    α-Amylase/α-Glucosidase-IN-11

    		Amylases Glycosidase Endocrinology
    α-Amylase/α-Glucosidase-IN-11 (Compound 5d) is a isoxazolidine-isatin hybrid with significant antidiabetic activity. α-Amylase/α-Glucosidase-IN-11 competitively inhibits α-amylase (IC50 = 30.39 μM) and α-glucosidase (IC50 = 65.1 μM), two key digestive enzymes. α-Amylase/α-Glucosidase-IN-11 does not cross the blood-brain barrier .
    α-Amylase/α-Glucosidase-IN-11
  • HY-N11844
    Quercetin 3-(6″-caffeoylsophoroside)

    		Amylases Metabolic Disease
    Quercetin 3-(6″-caffeoylsophoroside) is an orally active α-amylase inhibitor, with an IC50 of 73.66 μg/mL. Quercetin 3-(6″-caffeoylsophoroside) presents in thehydro-methanolic extract of Cardamine hirsuta Linn. Quercetin 3-(6″-caffeoylsophoroside) shows the antidiabetic activities by oxidative stress reduction and α-amylase inhibition. Quercetin 3-(6″-caffeoylsophoroside) can be used for diabetes mellitus research .
    Quercetin 3-(6″-caffeoylsophoroside)
  • HY-N1425
    Tiliroside
    1 Publications Verification

    		 Others Metabolic Disease
    Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2  μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .
    Tiliroside
  • HY-N10064
    Ficusonolide

    		Others Metabolic Disease
    Ficusonolide has significant antidiabetic activity with a possible mechanism of interaction with dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1B (PTP-1B), α-glucosidase, and α-amylase.
    Ficusonolide
  • HY-N7729
    Sekikaic acid

    		Amylases Glycosidase Metabolic Disease
    Sekikaic acid is an α-glucosidase (Glucosidase) and α-amylase (Amylases) inhibitor with hypolipidemic, antioxidant and antidiabetic activities. Sekikaic acid significantly reduces LDL, total cholesterol, and total glyceride levels and causes pancreatic beta cell regeneration .
    Sekikaic acid
  • HY-W112651
    2,4,6-Triphenylaniline

    		Glycosidase Amylases Metabolic Disease
    2,4,6-Triphenylaniline has anti-diabetic activity and can be encapsulated in nano-emulsions (NE) to enhance stability and permeability. The NE loaded with 2,4,6-Triphenylaniline inhibits α-glucosidase and α-amylase .
    2,4,6-Triphenylaniline
  • HY-153102
    G3-CNP

    		Biochemical Assay Reagents Others
    G3-CNP is an α-amylase substrate. The absorbance of G3-CNP cleavage product 2-chloro-4-nitrophenol is measured at 405 nm, which can be used to detect enzyme activity .
    G3-CNP
  • HY-N1425R
    Tiliroside (Standard)

    		Reference Standards Others Metabolic Disease
    Tiliroside (Standard) is the analytical standard of Tiliroside. This product is intended for research and analytical applications. Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract .
    Tiliroside (Standard)
  • HY-169737
    Inulobiose

    		Glycosidase Amylases Metabolic Disease
    Inulobiose is a difructan disaccharide that can be isolated from Pistacia vera L.. Inulobiose inhibits α-glycosidase and α-amylase activities with IC50s of 1.87 and 40.72 mg/mL, respectively. Inulobiose can be used for the research of diabetes and glomerular filtration rate testing .
    Inulobiose
  • HY-149313
    α‑Amylase-IN-1

    		Amylases Metabolic Disease
    α Amylase-IN-1 (Compound 11) is an α-Amylase inhibitor with an IC50 value of 0.5509 μM. α Amylase-IN-1 has antioxidant activity with an IC50 value of 53.49 μM for scavenging DPPH free radicals. IC50 can be used in the study of diabetes and oxidative stress-related diseases.
    α‑Amylase-IN-1
  • HY-161429
    Antidiabetic agent 5

    		Amylases Glycosidase Metabolic Disease
    Antidiabetic agent 5 (compound S1) is a antidiabetic agent. Antidiabetic agent 5 inhibits the activity of α-glucosidase and α-amylase with IC50 values of 3.91，8.89 μM，respectively. Antidiabetic agent 5 decreases sugar levels. Antidiabetic agent 5 has the potential for the research of type-II diabetes .
    Antidiabetic agent 5
  • HY-Y0598
    trans-Chalcone

    		Fatty Acid Synthase (FASN) Apoptosis Fungal Inflammation/Immunology Cancer
    trans-Chalcone, isolated from Aronia melanocarpa skin, is a biphenolic core structure of flavonoids precursor. trans-Chalcone is a potent fatty acid synthase (FAS) and α-amylase inhibitor. trans-Chalcone causes cellcycle arrest and induces apoptosis in the breastcancer cell line MCF-7. trans-Chalcone has antifungal and anticancer activity .
    trans-Chalcone
  • HY-112835
    Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside

    pNP-G7

    		 Amylases Inflammation/Immunology
    Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside (pNP-G7) is the substrate of α-amylase. Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside is degraded by amylase in the presence of auxiliary enzymes (such as α-glucosidase) to release the chromophore, allowing the measurement of amylase activity. Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside can be used for the diagnosis of pancreatitis .
    Ethylidene-4-nitrophenyl-a-D-Maltoheptaoside
  • HY-126052
    Gnetol

    		COX Tyrosinase HDAC Metabolic Disease Cancer
    Gnetol is a phenolic compound isolated from the root of Gnetum montanum . Gnetol potently inhibits COX-1 (IC50 of 0.78 μM) and HDAC. Gnetol is a potent tyrosinase inhibitor with an IC50 of 4.5 μM for murine tyrosinase and suppresses melanin biosynthesis. Gnetol has antioxidant, antiproliferative, anticancer and hepatoprotective activity. Gnetol also possesses concentration-dependent α-Amylase, α-glucosidase, and adipogenesis activities .
    Gnetol
  • HY-W068682
    1-Hydroxyphenazine

    Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin

    		 Amylases Bacterial Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    1-Hydroxyphenazine (Hemipyocyanine; 1-Phenazinol; Hemi-pyocyanin) is an inhibitor for α-Amylase with an IC50 of 3.1 μg/mL . 1-Hydroxyphenazine exhibits anticancer and anti-inflammatory activity against cells A549, 1321N1 and RAW264.7, antifungal and antibacterial activity against strains Candida albicans, Aspergillus fumigatus, Escherichia coli and Xanthomonas campestris .
    1-Hydroxyphenazine
  • HY-159491
    DPP-4-IN-11

    		Dipeptidyl Peptidase Glycosidase Amylases Metabolic Disease
    DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM) .
    DPP-4-IN-11
  • HY-113159A
    Docosapentaenoic acid (22n-3) sodium

    Clupanodonic acid sodium

    		 Amylases Glycosidase Metabolic Disease Inflammation/Immunology
    Docosapentaenoic acid (22n-3) sodium is a component of phospholipids. Docosapentaenoic acid 22n-3 sodium has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 sodium increases cell vitality. Docosapentaenoic acid 22n-3 sodium has a weak anti-inflammatory effect .
    Docosapentaenoic acid (22n-3) sodium
  • HY-113159
    Docosapentaenoic acid (22n-3)

    Clupanodonic acid

    		 Amylases Glycosidase Metabolic Disease Inflammation/Immunology
    Docosapentaenoic acid (22n-3) is a component of phospholipids. Docosapentaenoic acid 22n-3 has inhibitory activity against α-amylase and α-glucosidase, with IC50s value of 17 μg/mL and 22 μg/mL, respectively. Docosapentaenoic acid 22n-3 increases cell vitality. Docosapentaenoic acid 22n-3 has a weak anti-inflammatory effect .
    Docosapentaenoic acid (22n-3)
  • HY-149973
    α-Amylase-IN-4

    		Amylases Metabolic Disease
    α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC50 value 17.83 ± 0.14 μg/mL .
    α-Amylase-IN-4
  • HY-168074
    4″-C18 EGCG

    		Amylases Glycosidase Metabolic Disease Inflammation/Immunology
    4″-C18 EGCG is a potent inhibitor of α-amylase and α-glucosidase with IC50 values of 3.74 and 0.81 μM, respectively. 4″-C18 EGCG inhibits carbohydrate hydrolases, reduces oxidative stress and inflammation, and exhibits antidiabetic activity. 4″-C18 EGCG also downregulates proinflammatory cytokines and is cytotoxic to primary human peripheral blood mononuclear cells (PBMCs), non-cancer cell lines 3T3-L1, and HEK 293 at 50 μM .
    4″-C18 EGCG
  • HY-N8134
    2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one

    		Dipeptidyl Peptidase Metabolic Disease
    2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one is a natural product found in the leaves and stem bark of M. glabra. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one displays binding affinities with dipeptidyl peptidase-4 (DPP-4) and α-Amylase. 2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one has potential antidiabetic activities .
    2-Methoxy-5-acetoxy-fruranogermacr-1(10)-en-6-one
  • HY-168185
    α-glucosidase/PTP1B-IN-1

    		Glycosidase Phosphatase Amylases Metabolic Disease
    α-glucosidase/PTP1B-IN-1 (compound 8a) is a potent α-glucosidase and PTP1B inhibitor with an IC50 value of 66.3 μM and 47.0 μM, respectively. α-glucosidase/PTP1B-IN-1 exhibits excellent activities against α-amylase with an IC50 of 30.62 μM. α-glucosidase/PTP1B-IN-1 can dock into the active pockets of α-glucosidase and PTP1B. α-glucosidase/PTP1B-IN-1 has potential to reduce the postprandial blood glucose and is used for Type 2 diabetes mellitus .
    α-glucosidase/PTP1B-IN-1
  • HY-P2055
    A-57696

    		Endogenous Metabolite Endocrinology
    A-57696 is a cholecystokinin antagonist with selective activity at cortical CCK-B receptors (IC50 = 25 nM). A-57696 behaves as a competitive antagonist in reversing CCK8-stimulated pancreatic alpha-amylase secretion and phosphatidylinositol degradation. A-57696 fails to induce gallbladder contraction and inhibits CCK8-induced contraction. A-57696 behaves as a partial agonist at CCK-B/gastrin receptors on NCI-H345 cells, achieving 80% of the maximal CCK8 response. A-57696 and CCK8 inhibit each other in a calcium mobilization assay .
    A-57696

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: